Loading…
First Tracks Biotherapeutics, Inc. is projected to rise to $63.47 by 2027, a +75% move from its current price of $36.24. TRAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $33.52 | $36.26 | $39.23 | +0.06% |
| Jul 14 | $32.47 | $36.29 | $40.55 | +0.13% |
| Jul 15 | $31.69 | $36.31 | $41.60 | +0.20% |
| Jul 16 | $31.05 | $36.33 | $42.51 | +0.26% |
| Jul 17 | $30.50 | $36.36 | $43.34 | +0.33% |
| Jul 18 | $30.02 | $36.38 | $44.10 | +0.39% |
| Jul 19 | $29.58 | $36.41 | $44.81 | +0.46% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $29.58 | $36.41 | $44.81 | +0.46% |
| Week 2 | $27.26 | $36.57 | $49.06 | +0.91% |
| Week 3 | $25.63 | $36.74 | $52.65 | +1.37% |
| Week 4 | $24.36 | $36.91 | $55.92 | +1.84% |
| Week 5 | $23.30 | $37.07 | $59.00 | +2.30% |
| Week 6 | $22.39 | $37.24 | $61.95 | +2.77% |
| Week 7 | $21.59 | $37.41 | $64.83 | +3.23% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
First Tracks Biotherapeutics, Inc. operates a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
Its products include ANB033, a novel anti-CD122 antagonist that targets the shared beta subunit of the IL-15 and IL-2 receptors; Rosnilimab, a antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues; and ANB101, a BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs).
First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. It was founded in 2019 and is based in San Diego, California.
The stock trades under the symbol TRAX and is currently priced at $32.40.
Market capitalization is $1.13B and the company holds a rank of 2480.
Near-term price outlook for 2026 shows an average price of $32.40 with a min of $15.32 and a max of $52.64, and the sentiment is NEUTRAL.
Longer-term forecasts depict a bullish trend, with the average price rising to $57.54 in 2027, $82.81 in 2028, $84.75 in 2029, and advancing to $89.16 in 2030 (max $180.44; min $43.88) with a 175.2% ROI; continuing higher through 2031–2050, including 2040 at $376.98 with a 1063.5% ROI and 2050 at $610.55 with a 1784.4% ROI.
A major floor 77.0% below — a decisive break under it would weaken the trend.
The nearest floor, 57.7% below — buyers have tended to step in here.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 38.5% above — clearing it would confirm fresh momentum.
Key TRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of TRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $25.85 | Buy | $28.07 | Buy |
| MA 10 | $22.03 | Buy | $24.15 | Buy |
| MA 20 | $19.74 | Buy | $21.26 | Buy |
| MA 50 | $18.71 | Buy | $19.49 | Buy |
| MA 100 | — | Neutral | — | Neutral |
| MA 200 | — | Neutral | — | Neutral |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 82.74 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 355.68 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 1.81 | Buy |
| ROC (12) | 103.82 | Buy |
| Bollinger %B (20,2) | 1.31 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.71 | Buy |
| Awesome (5,34) | 7.43 | Buy |
| Ultimate (7,14,28) | 86.80 | Sell |
| Momentum (10) | 19.87 | Buy |
| Aroon Osc (25) | 100.00 | Buy |
| Hull MA (9) | 30.55 | Buy |
| ADX (14) | 17.46 | Neutral |
| ATR (14) | 1.86 | Info |
Technical sentiment is BULLISH with RSI14 at 80.
The 30-day range spans $19.38 to $54.16. The 50-day moving average is $18.39, and the current price is $32.40, with a near-term resistance at $32.40 and support at $15.32.
Annualized volatility is 100%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $15.32 | $36.24 | $58.93 | 0% | Neutral | |
| $41.47 | $63.47 | $105.06 | +75% | Bullish | |
| $53.02 | $90.00 | $162.18 | +148% | Bullish | |
| $49.52 | $92.17 | $177.03 | +154% | Bullish | |
| $47.21 | $95.88 | $193.98 | +165% | Bullish | |
| $44.44 | $98.26 | $207.81 | +171% | Bullish | |
| $54.15 | $120.33 | $264.55 | +232% | Bullish | |
| $80.29 | $178.42 | $406.04 | +392% | Bullish | |
| $88.90 | $197.55 | $454.38 | +445% | Bullish | |
| $94.02 | $208.93 | $480.54 | +477% | Bullish | |
| $174.78 | $388.39 | $893.31 | +972% | Bullish | |
| $282.44 | $627.65 | $1,443.61 | +16.3x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $15.32 | $36.24 | $48.46 | +0.00% |
| August 2026 | $32.50 | $40.45 | $53.08 | +11.62% |
| September 2026 | $30.23 | $38.45 | $51.98 | -4.95% |
| October 2026 | $29.85 | $38.71 | $53.64 | +0.67% |
| November 2026 | $31.49 | $41.50 | $58.69 | +7.21% |
| December 2026 | $30.56 | $40.90 | $58.93 | -1.44% |
Click any year to see its month-by-month TRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, TRAX could reach as high as $58.93, with a base case around $36.24 and support toward $15.32 — roughly 0% from $36.24. Price action looks broadly range-bound.
Expect TRAX to range from $41.47 to $105.06 through 2027. The $63.47 average target implies a +75% move from current prices. That is up +75% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The TRAX price prediction for 2028 points to an average of $90.00 (low $53.02, high $162.18) — a potential gain of +148% on today's $36.24. Momentum favours further upside here.
In 2029, TRAX is projected to trade between $49.52 and $177.03, averaging $92.17 — a potential gain of +154% from today's $36.24. That is up +2% on the projected 2028 average. Buyers look set to stay in control over this stretch.
First Tracks Biotherapeutics, Inc.'s 2030 outlook centres on $95.88, within a $47.21 to $193.98 range. That is up +4% on the projected 2029 average. That marks a +165% change versus current levels. Momentum favours further upside here.
By 2031, TRAX could reach as high as $207.81, with a base case around $98.26 and support toward $44.44 — roughly +171% from $36.24. Buyers look set to stay in control over this stretch.
Expect TRAX to range from $54.15 to $264.55 through 2032. The $120.33 average target implies a +232% move from current prices. That is up +22% on the projected 2031 average. Momentum favours further upside here.
The TRAX price prediction for 2033 points to an average of $178.42 (low $80.29, high $406.04) — a potential gain of +392% on today's $36.24. Buyers look set to stay in control over this stretch.
In 2034, TRAX is projected to trade between $88.90 and $454.38, averaging $197.55 — a potential gain of +445% from today's $36.24. That is up +11% on the projected 2033 average. Momentum favours further upside here.
First Tracks Biotherapeutics, Inc.'s 2035 outlook centres on $208.93, within a $94.02 to $480.54 range. That is up +6% on the projected 2034 average. That marks a +477% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, TRAX could reach as high as $893.31, with a base case around $388.39 and support toward $174.78 — roughly +972% from $36.24. Momentum favours further upside here.
Expect TRAX to range from $282.44 to $1,443.61 through 2050. The $627.65 average target implies a +16.3x move from current prices. That is up +62% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in TRAX today (≈ 27.593819 TRAX) could be worth
$17,319.4
+$16,319.4 (+1632%) by 2050 · US Dollar
Based on the average projected TRAX price of $627.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in TRAXwould be worth at today's price.
$1,000 invested in TRAX on Apr 6, 2026 (≈ 52.631579 TRAX) would be worth
$1,907.37
+$907.37 (+90.7%) today · 1.91× · US Dollar
Based on a TRAX entry price of $19 vs. today's $36.24.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $19.3 | $1,877.72 | +87.8% |
| 1 month ago | $16.42 | $2,207.06 | +120.7% |
| 3 months ago | $23.5 | $1,542.13 | +54.2% |
| All time ago | $19 | $1,907.37 | +90.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our TRAX forecast.
Our base-case forecast reaches $72.00 around 2028.
Implied market cap at $72.00: $2.51B
The multi-year forecast shows continued bullish sentiment across the horizon. In 2027 the average price is $57.54 with a 77.6% ROI, and in 2028 the average is $82.81 with a 155.6% ROI. By 2030 the average reaches $89.16 with a 175.2% ROI, and in 2031 the average is $92.41 with an 185.2% ROI.
From 2032 to 2035, the forecast continues higher: 2032 average $112.30 (246.6% ROI), 2033 $168.40 (419.8%), 2034 $187.96 (480.1%), and 2035 $198.57 (512.9%). The horizon extends to 2040 with an average of $376.98 (1063.5% ROI) and 2050 with an average of $610.55 (1784.4% ROI).
These figures illustrate sizable potential upside but remain estimates, not guarantees, and are subject to market and clinical development risks.
Tap a question to reveal the answer.
2030: avg $89.16, min $43.88, max $180.44, ROI 175.2%, sentiment BULLISH.
Forecasts show sentiment turning BULLISH from 2027 onward with rising averages and ROI up to 1784.4% by 2050; 2026 is NEUTRAL.
Yes—the 2030 max is $180.44, with an average of $89.16 and a ROI of 175.2%.
For 2026, the min is $15.32, the average is $32.40, and the max is $52.64; sentiment NEUTRAL.
RSI14 is 80; SMA50 is $18.39. The 30-day range is $19.38–$54.16 with support at $15.32 and resistance at $32.40; annualized volatility is 100%.
First Tracks Biotherapeutics, Inc. Community Discussion
0Share your First Tracks Biotherapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.